News
Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results